{"id":10899,"date":"2026-09-20T08:12:38","date_gmt":"2026-09-20T08:12:38","guid":{"rendered":"https:\/\/europepharmacy.eu\/?post_type=product&#038;p=10899"},"modified":"2026-09-20T08:12:40","modified_gmt":"2026-09-20T08:12:40","slug":"darunavir-300mg-tablets","status":"publish","type":"product","link":"https:\/\/europepharmacy.eu\/es\/shop\/darunavir-300mg-tablets\/","title":{"rendered":"Darunavir 300mg tablets"},"content":{"rendered":"<p data-path-to-node=\"11\">Darunavir (Prezista\u00ae) is an oral synthetic peptidomimetic inhibitor designed to overcome early-generation protease inhibitor mutations. Developed around a bis-tetrahydrofuranyl (<span class=\"math-inline\" data-math=\"\\text{bis-THF}\" data-index-in-node=\"178\">$\\text{bis-THF}$<\/span>) urethane scaffold, darunavir targets the catalytic core of the HIV-1 aspartyl protease enzyme with sub-nanomolar affinity. In contemporary antiretroviral regimens, it functions as a preferred anchor agent for both treatment-naive patients and individuals presenting with extensive multi-class antiretroviral drug failure.<\/p>\n<p data-path-to-node=\"12\"><b data-path-to-node=\"12\" data-index-in-node=\"0\">Clinical Profile &amp; Pharmaceutical Formulation<\/b><\/p>\n<ul data-path-to-node=\"13\">\n<li>\n<p data-path-to-node=\"13,0,0\"><b data-path-to-node=\"13,0,0\" data-index-in-node=\"0\">Active Pharmaceutical Ingredient:<\/b> Darunavir ethanolate (300 mg darunavir base equivalent per tablet).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"13,1,0\"><b data-path-to-node=\"13,1,0\" data-index-in-node=\"0\">Dosage Form &amp; Identification:<\/b> Film-coated, oval, biconvex tablet (typically white to off-white, debossed with strength identifiers such as &#8220;300&#8221; and manufacturer insignias).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"13,2,0\"><b data-path-to-node=\"13,2,0\" data-index-in-node=\"0\">Formulation Context:<\/b> The 300 mg dosage unit provides clinical flexibility. In heavily treatment-experienced adult patients with documented darunavir resistance-associated substitutions (RAMs), the standard dosing schedule consists of 600 mg (administered as two 300 mg tablets) co-administered with 100 mg of ritonavir twice daily (<span class=\"math-inline\" data-math=\"\\text{BID}\" data-index-in-node=\"332\">$\\text{BID}$<\/span>). It also serves as the titration unit for pediatric patients weighing <span class=\"math-inline\" data-math=\"\\ge 30\\text{ kg}\" data-index-in-node=\"414\">$\\ge 30\\text{ kg}$<\/span>.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"14\"><b data-path-to-node=\"14\" data-index-in-node=\"0\">Pharmacodynamics &amp; Mechanism of Action<\/b><\/p>\n<ul data-path-to-node=\"15\">\n<li>\n<p data-path-to-node=\"15,0,0\"><b data-path-to-node=\"15,0,0\" data-index-in-node=\"0\">Enzyme Binding Affinity:<\/b> Darunavir binds competitively into the hydrophobic substrate-binding groove of the homodimeric HIV-1 aspartyl protease enzyme.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,1,0\"><b data-path-to-node=\"15,1,0\" data-index-in-node=\"0\">Backbone Hydrogen Bonding:<\/b> Unlike earlier protease inhibitors that rely extensively on interactions with flexible protease amino acid side chains (which are prone to mutational drift), darunavir forms extensive, close-contact hydrogen bonds with the invariant main-chain peptide backbone of the enzyme (specifically residues Asp29 and Asp30).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,2,0\"><b data-path-to-node=\"15,2,0\" data-index-in-node=\"0\">Prevention of Polyprotein Cleavage:<\/b> By occupying the catalytic site, darunavir blocks the cleavage of the viral precursor polyproteins <span class=\"math-inline\" data-math=\"\\text{Gag}\" data-index-in-node=\"135\">$\\text{Gag}$<\/span> y <span class=\"math-inline\" data-math=\"\\text{Gag-Pol}\" data-index-in-node=\"150\">$\\text{Gag-Pol}$<\/span>. This prevents the formation of individual functional structural proteins (matrix, capsid, nucleocapsid) and essential replication enzymes (reverse transcriptase, integrase, protease), arresting post-translational maturation and yielding morphologically defective, non-infectious virions.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,3,0\"><b data-path-to-node=\"15,3,0\" data-index-in-node=\"0\">High Genetic Barrier to Resistance:<\/b> Because main-chain backbone geometries are structurally conserved to preserve catalytic function, the virus cannot easily alter these binding points without severely compromising its own enzymatic fitness. As a result, resistance typically requires the accumulation of multiple specific secondary mutations (e.g., V11I, V32I, L33F, I47V, I50V, I54L\/M, T74P, L76V, I84V, L89V).<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"16\"><b data-path-to-node=\"16\" data-index-in-node=\"0\">Pharmacokinetics &amp; Pharmacokinetic Boosting<\/b><\/p>\n<ul data-path-to-node=\"17\">\n<li>\n<p data-path-to-node=\"17,0,0\"><b data-path-to-node=\"17,0,0\" data-index-in-node=\"0\">Mandatory Pharmacokinetic Enhancement:<\/b> Darunavir undergoes extensive, rapid systemic metabolism when administered alone, resulting in subtherapeutic plasma troughs. It <b data-path-to-node=\"17,0,0\" data-index-in-node=\"168\">must<\/b> be co-administered with a pharmacokinetic booster\u2014either <b data-path-to-node=\"17,0,0\" data-index-in-node=\"230\">ritonavir<\/b> (100 mg) or <b data-path-to-node=\"17,0,0\" data-index-in-node=\"252\">cobicistat<\/b> (150 mg)\u2014which acts as a mechanism-based inhibitor of cytochrome P450 3A4 (<span class=\"math-inline\" data-math=\"\\text{CYP3A4}\" data-index-in-node=\"338\">$\\text{CYP3A4}$<\/span>). Boosting increases darunavir systemic exposure (<span class=\"math-inline\" data-math=\"\\text{AUC}\" data-index-in-node=\"402\">$\\text{AUC}$<\/span>) by approximately 14-fold.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,1,0\"><b data-path-to-node=\"17,1,0\" data-index-in-node=\"0\">Absorption &amp; Food Effect:<\/b> Rapidly absorbed following oral ingestion; peak plasma concentrations (<span class=\"math-inline\" data-math=\"C_{\\max}\" data-index-in-node=\"97\">$C_{\\max}$<\/span>) are reached within 2.5 to 4 hours post-dose. Systemic bioavailability is significantly amplified in the presence of food (increasing <span class=\"math-inline\" data-math=\"\\text{AUC}\" data-index-in-node=\"240\">$\\text{AUC}$<\/span> by ~30%); administration with a meal is mandatory.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,2,0\"><b data-path-to-node=\"17,2,0\" data-index-in-node=\"0\">Distribution &amp; Protein Binding:<\/b> High affinity for circulating plasma proteins (~95%), binding predominantly to human <span class=\"math-inline\" data-math=\"\\alpha_1\" data-index-in-node=\"117\">$\\alpha_1$<\/span>-acid glycoprotein (<span class=\"math-inline\" data-math=\"\\text{AAG}\" data-index-in-node=\"145\">$\\text{AAG}$<\/span>).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,3,0\"><b data-path-to-node=\"17,3,0\" data-index-in-node=\"0\">Elimination &amp; Kinetics:<\/b> Extensively metabolized hepatically by CYP3A4. Following boosted administration, terminal elimination half-life averages approximately 15 hours. Elimination occurs primarily through feces (~80%, containing unabsorbed drug and oxidative metabolites) and secondarily through urine (~13%).<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"18\"><b data-path-to-node=\"18\" data-index-in-node=\"0\">Clinical Administration &amp; Prescribing Guidelines<\/b><\/p>\n<ul data-path-to-node=\"19\">\n<li>\n<p data-path-to-node=\"19,0,0\"><b data-path-to-node=\"19,0,0\" data-index-in-node=\"0\">Indications:<\/b> Treatment of HIV-1 infection in treatment-naive and treatment-experienced adults and pediatric patients aged 3 years and older (weighing at least 15 kg).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,0\"><b data-path-to-node=\"19,1,0\" data-index-in-node=\"0\">Dosing Regimens:<\/b><\/p>\n<ul data-path-to-node=\"19,1,1\">\n<li>\n<p data-path-to-node=\"19,1,1,0,0\"><i data-path-to-node=\"19,1,1,0,0\" data-index-in-node=\"0\">Treatment-Naive Adults &amp; Experienced Adults without Darunavir Resistance Mutations:<\/i> 800 mg once daily with 100 mg ritonavir (or 150 mg cobicistat) with food.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,1,1,0\"><i data-path-to-node=\"19,1,1,1,0\" data-index-in-node=\"0\">Treatment-Experienced Adults with <span class=\"math-inline\" data-math=\"\\ge 1\" data-index-in-node=\"34\">$\\ge 1$<\/span> Darunavir Resistance Mutation:<\/i> 600 mg (two 300 mg tablets) co-administered with 100 mg ritonavir twice daily with food.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p data-path-to-node=\"19,2,0\"><b data-path-to-node=\"19,2,0\" data-index-in-node=\"0\">Administration Mandate:<\/b> Tablets must be swallowed whole with water during or immediately after a meal. Crushing or splitting is discouraged to maintain dose integrity.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"20\"><b data-path-to-node=\"20\" data-index-in-node=\"0\">Safety Considerations, Boxed Warnings, &amp; Monitoring<\/b><\/p>\n<ul data-path-to-node=\"21\">\n<li>\n<p data-path-to-node=\"21,0,0\"><b data-path-to-node=\"21,0,0\" data-index-in-node=\"0\">Severe Cutaneous Adverse Reactions (SCAR):<\/b> Severe skin reactions, including erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported. Therapy must be discontinued immediately if severe rash, blistering, mucosal lesions, or systemic febrile reactions develop.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,1,0\"><b data-path-to-node=\"21,1,0\" data-index-in-node=\"0\">Sulfa Allergy Precautions:<\/b> Darunavir contains a sulfonamide moiety. Use with caution in patients with known sulfonamide (sulfa) hypersensitivity, as potential cross-reactivity exists.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,2,0\"><b data-path-to-node=\"21,2,0\" data-index-in-node=\"0\">Hepatotoxicity:<\/b> Drug-induced hepatitis, including acute transaminase elevations and clinical jaundice, has been observed. Baseline and periodic hepatic function testing (AST, ALT, total bilirubin) is required, particularly in patients with pre-existing hepatitis B or C virus co-infection.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,3,0\"><b data-path-to-node=\"21,3,0\" data-index-in-node=\"0\">Metabolic Derangements:<\/b> Class-associated protease inhibitor side effects include hypertriglyceridemia, hypercholesterolemia, insulin resistance\/new-onset diabetes mellitus, and body fat redistribution (lipodystrophy).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,4,0\"><b data-path-to-node=\"21,4,0\" data-index-in-node=\"0\">Extensive Drug Interactions:<\/b> Because darunavir is co-administered with potent CYP3A inhibitors (ritonavir\/cobicistat), it significantly elevates plasma levels of co-administered drugs cleared via CYP3A. Concurrent use is contraindicated with agents like statins (simvastatin, lovastatin), sedatives (oral midazolam, triazolam), ergot derivatives, PDE5 inhibitors (for pulmonary arterial hypertension), and certain antiarrhythmics (amiodarone, quinidine).<\/p>\n<\/li>\n<\/ul>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"excerpt":{"rendered":"<p>Darunavir 300 mg (as darunavir ethanolate) is a prescription-only, second-generation non-peptidic protease inhibitor (PI) indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Engineered with an exceptionally high genetic barrier to resistance, darunavir must be co-administered with a low-dose pharmacokinetic enhancer (such as ritonavir or cobicistat) and taken with food to achieve therapeutic systemic exposure. The 300 mg tablet formulation is primarily utilized in multi-tablet titration schedules\u2014notably twice-daily regimens for treatment-experienced patients harboring baseline protease inhibitor resistance mutations\u2014as well as pediatric weight-based protocols. Dispensed strictly by medical prescription<\/p>","protected":false},"featured_media":10904,"comment_status":"open","ping_status":"closed","template":"","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""}},"product_brand":[],"product_cat":[506,1073,290],"product_tag":[1103,1122,1116,1123,1117,1118,1105,1119,1120,1121],"class_list":["post-10899","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-viral","product_cat-hivaid","product_cat-research-chemicals","product_tag-antiretroviral-therapy","product_tag-cobicistat-booster","product_tag-darunavir-300mg","product_tag-gag-pol-inhibitor","product_tag-generic-prezista","product_tag-hiv-1-protease-inhibitor","product_tag-prescription-hiv-medication","product_tag-ritonavir-boosted-darunavir","product_tag-second-generation-pi","product_tag-treatment-experienced-hiv","instock","sale","shipping-taxable","purchasable","product-type-simple"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Darunavir 300mg tablets<\/title>\n<meta name=\"description\" content=\"Darunavir 300 mg tablets: Second-generation HIV-1 protease inhibitor co-administered with pharmacokinetic boosters. Mechanism, resistance barrier, and clinical safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/europepharmacy.eu\/es\/shop\/darunavir-300mg-tablets\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Darunavir 300mg tablets\" \/>\n<meta property=\"og:description\" content=\"Darunavir 300 mg (as darunavir ethanolate) is a prescription-only, second-generation non-peptidic protease inhibitor (PI) indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Engineered with an exceptionally high genetic barrier to resistance, darunavir must be co-administered with a low-dose pharmacokinetic enhancer (such as ritonavir or cobicistat) and taken with food to achieve therapeutic systemic exposure. The 300 mg tablet formulation is primarily utilized in multi-tablet titration schedules\u2014notably twice-daily regimens for treatment-experienced patients harboring baseline protease inhibitor resistance mutations\u2014as well as pediatric weight-based protocols. Dispensed strictly by medical prescription\" \/>\n<meta property=\"og:url\" content=\"https:\/\/europepharmacy.eu\/es\/shop\/darunavir-300mg-tablets\/\" \/>\n<meta property=\"og:site_name\" content=\"European Pharmacy\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T08:12:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/medicine-drugs-white.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/\",\"name\":\"Darunavir 300mg tablets\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/medicine-drugs-white.png\",\"datePublished\":\"2026-09-20T08:12:38+00:00\",\"dateModified\":\"2026-09-20T08:12:40+00:00\",\"description\":\"Darunavir 300 mg tablets: Second-generation HIV-1 protease inhibitor co-administered with pharmacokinetic boosters. Mechanism, resistance barrier, and clinical safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/medicine-drugs-white.png\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/medicine-drugs-white.png\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/darunavir-300mg-tablets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Darunavir 300mg tablets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"name\":\"European Pharmacy\",\"description\":\"Order Medication &amp; Pills Online\",\"publisher\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/europepharmacy.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\",\"name\":\"European Pharmacy\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"width\":1254,\"height\":1254,\"caption\":\"European Pharmacy\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Darunavir 300mg tablets","description":"Darunavir 300 mg tablets: Second-generation HIV-1 protease inhibitor co-administered with pharmacokinetic boosters. Mechanism, resistance barrier, and clinical safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/europepharmacy.eu\/es\/shop\/darunavir-300mg-tablets\/","og_locale":"es_ES","og_type":"article","og_title":"Darunavir 300mg tablets","og_description":"Darunavir 300 mg (as darunavir ethanolate) is a prescription-only, second-generation non-peptidic protease inhibitor (PI) indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Engineered with an exceptionally high genetic barrier to resistance, darunavir must be co-administered with a low-dose pharmacokinetic enhancer (such as ritonavir or cobicistat) and taken with food to achieve therapeutic systemic exposure. The 300 mg tablet formulation is primarily utilized in multi-tablet titration schedules\u2014notably twice-daily regimens for treatment-experienced patients harboring baseline protease inhibitor resistance mutations\u2014as well as pediatric weight-based protocols. Dispensed strictly by medical prescription","og_url":"https:\/\/europepharmacy.eu\/es\/shop\/darunavir-300mg-tablets\/","og_site_name":"European Pharmacy","article_modified_time":"2026-09-20T08:12:40+00:00","og_image":[{"width":2000,"height":2000,"url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/medicine-drugs-white.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/","url":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/","name":"Darunavir 300mg tablets","isPartOf":{"@id":"https:\/\/europepharmacy.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/#primaryimage"},"image":{"@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/#primaryimage"},"thumbnailUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/medicine-drugs-white.png","datePublished":"2026-09-20T08:12:38+00:00","dateModified":"2026-09-20T08:12:40+00:00","description":"Darunavir 300 mg tablets: Second-generation HIV-1 protease inhibitor co-administered with pharmacokinetic boosters. Mechanism, resistance barrier, and clinical safety.","breadcrumb":{"@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/#primaryimage","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/medicine-drugs-white.png","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/medicine-drugs-white.png","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/europepharmacy.eu\/shop\/darunavir-300mg-tablets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/europepharmacy.eu\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/europepharmacy.eu\/shop\/"},{"@type":"ListItem","position":3,"name":"Darunavir 300mg tablets"}]},{"@type":"WebSite","@id":"https:\/\/europepharmacy.eu\/#website","url":"https:\/\/europepharmacy.eu\/","name":"European Pharmacy","description":"Order Medication &amp; Pills Online","publisher":{"@id":"https:\/\/europepharmacy.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/europepharmacy.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/europepharmacy.eu\/#organization","name":"European Pharmacy","url":"https:\/\/europepharmacy.eu\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","width":1254,"height":1254,"caption":"European Pharmacy"},"image":{"@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product\/10899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/comments?post=10899"}],"version-history":[{"count":2,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product\/10899\/revisions"}],"predecessor-version":[{"id":10907,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product\/10899\/revisions\/10907"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/media\/10904"}],"wp:attachment":[{"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/media?parent=10899"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product_brand?post=10899"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product_cat?post=10899"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/europepharmacy.eu\/es\/wp-json\/wp\/v2\/product_tag?post=10899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}